Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers

Thaer S. A. Abdalla,Jannis Duhn,Monika Klinkhammer-Schalke,Sylke Ruth Zeissig,Kees Kleihues-van Tol,Kim C. Honselmann,Rüdiger Braun,Markus Kist,Louisa Bolm,Lennart von Fritsch,Hryhoriy Lapshyn,Stanislav Litkevych,Richard Hummel,Sergii Zemskov,Ulrich Friedrich Wellner,Tobias Keck,Steffen Deichmann
DOI: https://doi.org/10.3390/cancers16112016
2024-05-27
Cancers
Abstract:Background: Intraductal papillary mucinous neoplasms (IPMNs) are premalignant cystic neoplasms of the pancreas (CNPs), which can progress to invasive IPMN and pancreatic cancer. The available literature has shown controversial results regarding prognosis and clinical outcomes after the resection of invasive IPMN. Aims: This study aims to characterize the oncologic outcomes and metastatic progression pattern after the resection of non-metastatic invasive IPMN. Methods: Data were obtained from 24 clinical cancer registries participating in the German Cancer Registry Group of the Society of German Tumor Centers (ADT). Patients with invasive IPMN (n = 217) as well as PDAC (n = 5794) between 2000 and 2021 were included and compared regarding oncological outcomes. Results: Invasive IPMN was significantly smaller in size (p < 0.001) and of a lower tumor grade (p < 0.001), with fewer lymph node metastases (p < 0.001), lymphangiosis (p < 0.001), and consequently a higher R0 resection rate (88 vs. 74%) compared to PDAC. Moreover, invasive IPMN was associated with fewer local (11 vs. 15%) and distant recurrences (29 vs. 46%) and metastasized more frequently in the lungs only (26% vs. 14%). Invasive IPMN was associated with a longer median OS (29 vs. 19 months) and DFS (31 vs. 15 months) compared to PDAC and stayed independently prognostic in multivariable analyses. These survival differences were most pronounced in early tumor stages. Interestingly, postoperative chemotherapy was not associated with improved overall survival in surgically resected invasive IPMN. Conclusions: Invasive IPMN is a rare pancreatic entity with increasing incidence in Germany. It is associated with favorable histopathological features at the time of resection and longer OS and DFS compared to PDAC, particularly before the locoregional spread has occurred. Invasive IPMNs are associated with lung-only metastasis. The benefit of postoperative chemotherapy after the resection of invasive IPMN remains uncertain.
oncology
What problem does this paper attempt to address?
What problem does this paper aim to address? This paper attempts to address the differences in oncological outcomes and recurrence patterns following surgical resection of invasive intraductal papillary mucinous neoplasm (invasive IPMN) and primary pancreatic ductal adenocarcinoma (PDAC). Specifically, the study analyzes data from the German Cancer Registry Group to compare overall survival, disease-free survival, and recurrence between these two types of pancreatic tumors after surgical resection. It also explores whether the biological characteristics of invasive IPMN are more advantageous than those of PDAC. Additionally, the study examines the impact of postoperative chemotherapy on these two types of tumors. The results indicate that invasive IPMN has better prognostic features, especially in the early stages, and its recurrence patterns differ significantly from those of PDAC.